BioLife Solutions, Inc. (NASDAQ: BLFS) Stock Competitors & Peer Comparison
See BLFS's competitors and their performance on the NASDAQ and across the wider stock market.
Peer Comparison Table: Medical - Instruments & Supplies Industry
Detailed financial metrics including price, market cap, P/E ratio, and more for BLFS and its NASDAQ peers.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BLFS | $38.61 | +0.00% | 1.9B | 37.49 | $1.03 | N/A |
| ISRG | $414.52 | +2.41% | 146.4B | 43.09 | $9.62 | N/A |
| BDXA | $59.24 | -2.24% | 55.9B | 45.70 | $1.30 | +2.20% |
| BDX | $180.16 | -0.08% | 49.6B | 13.86 | $13.00 | +2.20% |
| RMD | $225.98 | +2.40% | 32.8B | 20.98 | $10.77 | +1.12% |
| MDLN | $35.45 | -0.28% | 30B | 25.98 | $1.36 | N/A |
| WST | $366.48 | -1.65% | 25.8B | 43.11 | $8.50 | +0.24% |
| HOLX | $76.01 | +0.00% | 17B | 31.54 | $2.41 | N/A |
| SOLV | $85.88 | -1.33% | 14.9B | 12.09 | $7.10 | N/A |
| BDXB | $48.16 | +1.39% | 13.7B | 7.60 | $6.33 | +2.20% |
Stock Comparison
Intuitive Surgical, Inc. (NASDAQ: ISRG)
BLFS vs ISRG Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ISRG has a market cap of 146.4B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ISRG trades at $414.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ISRG's P/E ratio is 43.09. In terms of profitability, BLFS's ROE is +0.13%, compared to ISRG's ROE of +0.18%. Regarding short-term risk, BLFS is more volatile compared to ISRG. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ISRG's competition here
Becton, Dickinson and Company (NYSE: BDXA)
BLFS vs BDXA Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BDXA has a market cap of 55.9B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BDXA trades at $59.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BDXA's P/E ratio is 45.70. In terms of profitability, BLFS's ROE is +0.13%, compared to BDXA's ROE of +0.04%. Regarding short-term risk, BLFS is less volatile compared to BDXA. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check BDXA's competition here
Becton, Dickinson and Company (NYSE: BDX)
BLFS vs BDX Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BDX has a market cap of 49.6B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BDX trades at $180.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BDX's P/E ratio is 13.86. In terms of profitability, BLFS's ROE is +0.13%, compared to BDX's ROE of +0.04%. Regarding short-term risk, BLFS is more volatile compared to BDX. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check BDX's competition here
ResMed Inc. (NYSE: RMD)
BLFS vs RMD Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, RMD has a market cap of 32.8B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while RMD trades at $225.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas RMD's P/E ratio is 20.98. In terms of profitability, BLFS's ROE is +0.13%, compared to RMD's ROE of +0.24%. Regarding short-term risk, BLFS is more volatile compared to RMD. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check RMD's competition here
Medline Inc. (NASDAQ: MDLN)
BLFS vs MDLN Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, MDLN has a market cap of 30B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while MDLN trades at $35.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas MDLN's P/E ratio is 25.98. In terms of profitability, BLFS's ROE is +0.13%, compared to MDLN's ROE of +0.05%. Regarding short-term risk, BLFS is more volatile compared to MDLN. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check MDLN's competition here
West Pharmaceutical Services, Inc. (NYSE: WST)
BLFS vs WST Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, WST has a market cap of 25.8B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while WST trades at $366.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas WST's P/E ratio is 43.11. In terms of profitability, BLFS's ROE is +0.13%, compared to WST's ROE of +0.19%. Regarding short-term risk, BLFS is more volatile compared to WST. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check WST's competition here
Hologic, Inc. (NASDAQ: HOLX)
BLFS vs HOLX Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, HOLX has a market cap of 17B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while HOLX trades at $76.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas HOLX's P/E ratio is 31.54. In terms of profitability, BLFS's ROE is +0.13%, compared to HOLX's ROE of +0.11%. Regarding short-term risk, BLFS is more volatile compared to HOLX. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check HOLX's competition here
Solventum Corporation (NYSE: SOLV)
BLFS vs SOLV Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, SOLV has a market cap of 14.9B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while SOLV trades at $85.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas SOLV's P/E ratio is 12.09. In terms of profitability, BLFS's ROE is +0.13%, compared to SOLV's ROE of +0.29%. Regarding short-term risk, BLFS is more volatile compared to SOLV. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check SOLV's competition here
Becton, Dickinson and Company (NYSE: BDXB)
BLFS vs BDXB Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BDXB has a market cap of 13.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BDXB trades at $48.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BDXB's P/E ratio is 7.60. In terms of profitability, BLFS's ROE is +0.13%, compared to BDXB's ROE of +0.04%. Regarding short-term risk, BLFS is more volatile compared to BDXB. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check BDXB's competition here
Baxter International Inc. (NYSE: BAX)
BLFS vs BAX Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BAX has a market cap of 12.4B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BAX trades at $23.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BAX's P/E ratio is 11.52. In terms of profitability, BLFS's ROE is +0.13%, compared to BAX's ROE of -0.17%. Regarding short-term risk, BLFS is more volatile compared to BAX. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check BAX's competition here
The Cooper Companies, Inc. (NASDAQ: COO)
BLFS vs COO Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, COO has a market cap of 10.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while COO trades at $54.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas COO's P/E ratio is 12.01. In terms of profitability, BLFS's ROE is +0.13%, compared to COO's ROE of +0.07%. Regarding short-term risk, BLFS is more volatile compared to COO. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check COO's competition here
Avantor, Inc. (NYSE: AVTR)
BLFS vs AVTR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, AVTR has a market cap of 10.4B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while AVTR trades at $15.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas AVTR's P/E ratio is 18.05. In terms of profitability, BLFS's ROE is +0.13%, compared to AVTR's ROE of -0.10%. Regarding short-term risk, BLFS is more volatile compared to AVTR. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check AVTR's competition here
Repligen Corporation (NASDAQ: RGEN)
BLFS vs RGEN Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, RGEN has a market cap of 9.5B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while RGEN trades at $167.22.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas RGEN's P/E ratio is 93.14. In terms of profitability, BLFS's ROE is +0.13%, compared to RGEN's ROE of +0.02%. Regarding short-term risk, BLFS is less volatile compared to RGEN. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check RGEN's competition here
AptarGroup, Inc. (NYSE: ATR)
BLFS vs ATR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ATR has a market cap of 7.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ATR trades at $120.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ATR's P/E ratio is 21.05. In terms of profitability, BLFS's ROE is +0.13%, compared to ATR's ROE of +0.14%. Regarding short-term risk, BLFS is more volatile compared to ATR. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ATR's competition here
Bausch + Lomb Corporation (NYSE: BLCO)
BLFS vs BLCO Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BLCO has a market cap of 6.2B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BLCO trades at $17.34.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BLCO's P/E ratio is 26.68. In terms of profitability, BLFS's ROE is +0.13%, compared to BLCO's ROE of -0.03%. Regarding short-term risk, BLFS is more volatile compared to BLCO. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check BLCO's competition here
Teleflex Incorporated (NYSE: TFX)
BLFS vs TFX Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, TFX has a market cap of 5.5B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while TFX trades at $124.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas TFX's P/E ratio is 14.23. In terms of profitability, BLFS's ROE is +0.13%, compared to TFX's ROE of -0.32%. Regarding short-term risk, BLFS is more volatile compared to TFX. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check TFX's competition here
Stevanato Group S.p.A. (NYSE: STVN)
BLFS vs STVN Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, STVN has a market cap of 5.3B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while STVN trades at $19.44.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas STVN's P/E ratio is 29.44. In terms of profitability, BLFS's ROE is +0.13%, compared to STVN's ROE of +0.09%. Regarding short-term risk, BLFS is more volatile compared to STVN. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check STVN's competition here
Merit Medical Systems, Inc. (NASDAQ: MMSI)
BLFS vs MMSI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, MMSI has a market cap of 5.1B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while MMSI trades at $85.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas MMSI's P/E ratio is 21.76. In terms of profitability, BLFS's ROE is +0.13%, compared to MMSI's ROE of +0.09%. Regarding short-term risk, BLFS is more volatile compared to MMSI. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check MMSI's competition here
ICU Medical, Inc. (NASDAQ: ICUI)
BLFS vs ICUI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ICUI has a market cap of 3.9B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ICUI trades at $156.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ICUI's P/E ratio is 19.48. In terms of profitability, BLFS's ROE is +0.13%, compared to ICUI's ROE of +0.01%. Regarding short-term risk, BLFS is more volatile compared to ICUI. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ICUI's competition here
Envista Holdings Corp (NYSE: NVST)
BLFS vs NVST Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NVST has a market cap of 3.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NVST trades at $23.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NVST's P/E ratio is 15.67. In terms of profitability, BLFS's ROE is +0.13%, compared to NVST's ROE of +0.03%. Regarding short-term risk, BLFS is more volatile compared to NVST. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check NVST's competition here
Pulse Biosciences, Inc. (NASDAQ: PLSE)
BLFS vs PLSE Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, PLSE has a market cap of 3.4B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while PLSE trades at $49.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas PLSE's P/E ratio is -41.60. In terms of profitability, BLFS's ROE is +0.13%, compared to PLSE's ROE of -0.94%. Regarding short-term risk, BLFS is more volatile compared to PLSE. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check PLSE's competition here
AtriCure, Inc. (NASDAQ: ATRC)
BLFS vs ATRC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ATRC has a market cap of 2.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ATRC trades at $53.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ATRC's P/E ratio is 1655.59. In terms of profitability, BLFS's ROE is +0.13%, compared to ATRC's ROE of +0.02%. Regarding short-term risk, BLFS is more volatile compared to ATRC. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ATRC's competition here
LeMaitre Vascular, Inc. (NASDAQ: LMAT)
BLFS vs LMAT Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, LMAT has a market cap of 1.8B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while LMAT trades at $79.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas LMAT's P/E ratio is 29.16. In terms of profitability, BLFS's ROE is +0.13%, compared to LMAT's ROE of +0.16%. Regarding short-term risk, BLFS is more volatile compared to LMAT. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check LMAT's competition here
DENTSPLY SIRONA Inc. (NASDAQ: XRAY)
BLFS vs XRAY Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, XRAY has a market cap of 1.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while XRAY trades at $8.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas XRAY's P/E ratio is 5.97. In terms of profitability, BLFS's ROE is +0.13%, compared to XRAY's ROE of -0.40%. Regarding short-term risk, BLFS is more volatile compared to XRAY. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check XRAY's competition here
Azenta, Inc. (NASDAQ: AZTA)
BLFS vs AZTA Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, AZTA has a market cap of 1.7B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while AZTA trades at $35.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas AZTA's P/E ratio is 85.45. In terms of profitability, BLFS's ROE is +0.13%, compared to AZTA's ROE of -0.08%. Regarding short-term risk, BLFS is less volatile compared to AZTA. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check AZTA's competition here
Kestra Medical Technologies, Ltd. (NASDAQ: KMTS)
BLFS vs KMTS Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, KMTS has a market cap of 1.6B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while KMTS trades at $26.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas KMTS's P/E ratio is -10.00. In terms of profitability, BLFS's ROE is +0.13%, compared to KMTS's ROE of -0.64%. Regarding short-term risk, BLFS is less volatile compared to KMTS. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check KMTS's competition here
STAAR Surgical Company (NASDAQ: STAA)
BLFS vs STAA Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, STAA has a market cap of 1.1B. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while STAA trades at $22.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas STAA's P/E ratio is 39.23. In terms of profitability, BLFS's ROE is +0.13%, compared to STAA's ROE of +0.01%. Regarding short-term risk, BLFS is more volatile compared to STAA. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check STAA's competition here
Atrion Corporation (NASDAQ: ATRI)
BLFS vs ATRI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ATRI has a market cap of 809.4M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ATRI trades at $459.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ATRI's P/E ratio is 64.50. In terms of profitability, BLFS's ROE is +0.13%, compared to ATRI's ROE of +0.08%. Regarding short-term risk, BLFS is more volatile compared to ATRI. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ATRI's competition here
AngioDynamics, Inc. (NASDAQ: ANGO)
BLFS vs ANGO Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ANGO has a market cap of 586.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ANGO trades at $14.19.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ANGO's P/E ratio is -36.38. In terms of profitability, BLFS's ROE is +0.13%, compared to ANGO's ROE of -0.21%. Regarding short-term risk, BLFS is more volatile compared to ANGO. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ANGO's competition here
Embecta Corp. (NASDAQ: EMBC)
BLFS vs EMBC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, EMBC has a market cap of 350.6M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while EMBC trades at $5.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas EMBC's P/E ratio is 2.27. In terms of profitability, BLFS's ROE is +0.13%, compared to EMBC's ROE of -0.14%. Regarding short-term risk, BLFS is less volatile compared to EMBC. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check EMBC's competition here
Sanara MedTech Inc. (NASDAQ: SMTI)
BLFS vs SMTI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, SMTI has a market cap of 322.2M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while SMTI trades at $35.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas SMTI's P/E ratio is -584.17. In terms of profitability, BLFS's ROE is +0.13%, compared to SMTI's ROE of -4.74%. Regarding short-term risk, BLFS is more volatile compared to SMTI. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check SMTI's competition here
OraSure Technologies, Inc. (NASDAQ: OSUR)
BLFS vs OSUR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, OSUR has a market cap of 256.8M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while OSUR trades at $3.73.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas OSUR's P/E ratio is -5.41. In terms of profitability, BLFS's ROE is +0.13%, compared to OSUR's ROE of -0.15%. Regarding short-term risk, BLFS is less volatile compared to OSUR. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check OSUR's competition here
Utah Medical Products, Inc. (NASDAQ: UTMD)
BLFS vs UTMD Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, UTMD has a market cap of 233.9M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while UTMD trades at $73.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas UTMD's P/E ratio is 21.73. In terms of profitability, BLFS's ROE is +0.13%, compared to UTMD's ROE of +0.09%. Regarding short-term risk, BLFS is more volatile compared to UTMD. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check UTMD's competition here
Anbio Biotechnology Class A Ordinary Shares (NASDAQ: NNNN)
BLFS vs NNNN Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NNNN has a market cap of 215.1M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NNNN trades at $4.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NNNN's P/E ratio is 32.67. In terms of profitability, BLFS's ROE is +0.13%, compared to NNNN's ROE of +0.27%. Regarding short-term risk, BLFS is less volatile compared to NNNN. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check NNNN's competition here
Pro-Dex, Inc. (NASDAQ: PDEX)
BLFS vs PDEX Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, PDEX has a market cap of 200.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while PDEX trades at $62.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas PDEX's P/E ratio is 15.21. In terms of profitability, BLFS's ROE is +0.13%, compared to PDEX's ROE of +0.31%. Regarding short-term risk, BLFS is more volatile compared to PDEX. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check PDEX's competition here
KORU Medical Systems, Inc. (NASDAQ: KRMD)
BLFS vs KRMD Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, KRMD has a market cap of 136.9M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while KRMD trades at $2.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas KRMD's P/E ratio is -74.50. In terms of profitability, BLFS's ROE is +0.13%, compared to KRMD's ROE of -0.11%. Regarding short-term risk, BLFS is more volatile compared to KRMD. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check KRMD's competition here
Stereotaxis, Inc. (AMEX: STXS)
BLFS vs STXS Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, STXS has a market cap of 111.2M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while STXS trades at $1.13.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas STXS's P/E ratio is -6.68. In terms of profitability, BLFS's ROE is +0.13%, compared to STXS's ROE of -1.33%. Regarding short-term risk, BLFS is more volatile compared to STXS. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check STXS's competition here
Akoya Biosciences, Inc. (NASDAQ: AKYA)
BLFS vs AKYA Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, AKYA has a market cap of 64.4M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while AKYA trades at $1.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas AKYA's P/E ratio is -1.34. In terms of profitability, BLFS's ROE is +0.13%, compared to AKYA's ROE of -1.80%. Regarding short-term risk, BLFS is more volatile compared to AKYA. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check AKYA's competition here
Daxor Corporation (NASDAQ: DXR)
BLFS vs DXR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, DXR has a market cap of 61.4M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while DXR trades at $10.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas DXR's P/E ratio is 8.55. In terms of profitability, BLFS's ROE is +0.13%, compared to DXR's ROE of +0.13%. Regarding short-term risk, BLFS is less volatile compared to DXR. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check DXR's competition here
SkyAI, Inc. (NASDAQ: STSS)
BLFS vs STSS Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, STSS has a market cap of 53.7M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while STSS trades at $1.27.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas STSS's P/E ratio is -0.02. In terms of profitability, BLFS's ROE is +0.13%, compared to STSS's ROE of -1.54%. Regarding short-term risk, BLFS is less volatile compared to STSS. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check STSS's competition here
Singular Genomics Systems, Inc. (NASDAQ: OMIC)
BLFS vs OMIC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, OMIC has a market cap of 50.8M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while OMIC trades at $20.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas OMIC's P/E ratio is -0.58. In terms of profitability, BLFS's ROE is +0.13%, compared to OMIC's ROE of -0.43%. Regarding short-term risk, BLFS is more volatile compared to OMIC. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check OMIC's competition here
GlucoTrack, Inc. (NASDAQ: IGAP)
BLFS vs IGAP Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, IGAP has a market cap of 50.2M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while IGAP trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas IGAP's P/E ratio is -10.52. In terms of profitability, BLFS's ROE is +0.13%, compared to IGAP's ROE of +1.80%. Regarding short-term risk, BLFS is more volatile compared to IGAP. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check IGAP's competition here
Precision Optics Corporation, Inc. (NASDAQ: POCI)
BLFS vs POCI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, POCI has a market cap of 49.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while POCI trades at $4.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas POCI's P/E ratio is -9.83. In terms of profitability, BLFS's ROE is +0.13%, compared to POCI's ROE of -0.24%. Regarding short-term risk, BLFS is more volatile compared to POCI. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check POCI's competition here
Harvard Bioscience, Inc. (NASDAQ: HBIO)
BLFS vs HBIO Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, HBIO has a market cap of 38.3M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while HBIO trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas HBIO's P/E ratio is -23.61. In terms of profitability, BLFS's ROE is +0.13%, compared to HBIO's ROE of -0.92%. Regarding short-term risk, BLFS is more volatile compared to HBIO. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check HBIO's competition here
Nephros, Inc. (NASDAQ: NEPH)
BLFS vs NEPH Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NEPH has a market cap of 34.7M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NEPH trades at $3.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NEPH's P/E ratio is 53.33. In terms of profitability, BLFS's ROE is +0.13%, compared to NEPH's ROE of +0.16%. Regarding short-term risk, BLFS is less volatile compared to NEPH. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check NEPH's competition here
Milestone Scientific Inc. (AMEX: MLSS)
BLFS vs MLSS Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, MLSS has a market cap of 33.3M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while MLSS trades at $0.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas MLSS's P/E ratio is -7.54. In terms of profitability, BLFS's ROE is +0.13%, compared to MLSS's ROE of -1.49%. Regarding short-term risk, BLFS is more volatile compared to MLSS. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check MLSS's competition here
SmileDirectClub, Inc. (NASDAQ: SDC)
BLFS vs SDC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, SDC has a market cap of 29.1M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while SDC trades at $0.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas SDC's P/E ratio is -0.03. In terms of profitability, BLFS's ROE is +0.13%, compared to SDC's ROE of -1.96%. Regarding short-term risk, BLFS is less volatile compared to SDC. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check SDC's competition here
Invacare Corporation (NYSE: IVC)
BLFS vs IVC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, IVC has a market cap of 24.9M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while IVC trades at $0.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas IVC's P/E ratio is -0.79. In terms of profitability, BLFS's ROE is +0.13%, compared to IVC's ROE of -0.46%. Regarding short-term risk, BLFS is less volatile compared to IVC. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check IVC's competition here
Retractable Technologies, Inc. (AMEX: RVP)
BLFS vs RVP Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, RVP has a market cap of 20.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while RVP trades at $0.69.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas RVP's P/E ratio is -5.69. In terms of profitability, BLFS's ROE is +0.13%, compared to RVP's ROE of -0.05%. Regarding short-term risk, BLFS is more volatile compared to RVP. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check RVP's competition here
Bionano Genomics, Inc. (NASDAQ: BNGO)
BLFS vs BNGO Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, BNGO has a market cap of 16.8M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while BNGO trades at $1.46.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas BNGO's P/E ratio is -0.48. In terms of profitability, BLFS's ROE is +0.13%, compared to BNGO's ROE of -0.79%. Regarding short-term risk, BLFS is more volatile compared to BNGO. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check BNGO's competition here
Jin Medical International Ltd. (NASDAQ: ZJYL)
BLFS vs ZJYL Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ZJYL has a market cap of 16.6M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ZJYL trades at $2.12.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ZJYL's P/E ratio is 14.50. In terms of profitability, BLFS's ROE is +0.13%, compared to ZJYL's ROE of +0.04%. Regarding short-term risk, BLFS is less volatile compared to ZJYL. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check ZJYL's competition here
Regentis Biomaterials Ltd. (AMEX: RGNT)
BLFS vs RGNT Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, RGNT has a market cap of 11.4M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while RGNT trades at $1.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas RGNT's P/E ratio is -0.66. In terms of profitability, BLFS's ROE is +0.13%, compared to RGNT's ROE of N/A. Regarding short-term risk, BLFS is more volatile compared to RGNT. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check RGNT's competition here
Femasys Inc. (NASDAQ: FEMY)
BLFS vs FEMY Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, FEMY has a market cap of 6M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while FEMY trades at $2.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas FEMY's P/E ratio is -0.45. In terms of profitability, BLFS's ROE is +0.13%, compared to FEMY's ROE of -2.26%. Regarding short-term risk, BLFS is more volatile compared to FEMY. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check FEMY's competition here
Lucyd, Inc (NASDAQ: LUCY)
BLFS vs LUCY Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, LUCY has a market cap of 5.7M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while LUCY trades at $0.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas LUCY's P/E ratio is -0.71. In terms of profitability, BLFS's ROE is +0.13%, compared to LUCY's ROE of -0.89%. Regarding short-term risk, BLFS is more volatile compared to LUCY. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check LUCY's competition here
Cuprina Holdings (Cayman) Limited Class A Ordinary Shares (NASDAQ: CUPR)
BLFS vs CUPR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, CUPR has a market cap of 5.1M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while CUPR trades at $1.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas CUPR's P/E ratio is -1.38. In terms of profitability, BLFS's ROE is +0.13%, compared to CUPR's ROE of -15.69%. Regarding short-term risk, BLFS is less volatile compared to CUPR. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check CUPR's competition here
NanoString Technologies, Inc. (NASDAQ: NSTG)
BLFS vs NSTG Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NSTG has a market cap of 5.1M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NSTG trades at $0.11.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NSTG's P/E ratio is -0.03. In terms of profitability, BLFS's ROE is +0.13%, compared to NSTG's ROE of -1.43%. Regarding short-term risk, BLFS is less volatile compared to NSTG. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check NSTG's competition here
Predictive Oncology Inc. (NASDAQ: POAI)
BLFS vs POAI Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, POAI has a market cap of 3.6M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while POAI trades at $4.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas POAI's P/E ratio is -0.38. In terms of profitability, BLFS's ROE is +0.13%, compared to POAI's ROE of -21.19%. Regarding short-term risk, BLFS is less volatile compared to POAI. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check POAI's competition here
Meihua International Medical Technologies Co., Ltd. (NASDAQ: MHUA)
BLFS vs MHUA Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, MHUA has a market cap of 2.4M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while MHUA trades at $7.61.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas MHUA's P/E ratio is 0.25. In terms of profitability, BLFS's ROE is +0.13%, compared to MHUA's ROE of +0.07%. Regarding short-term risk, BLFS is more volatile compared to MHUA. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check MHUA's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVD)
BLFS vs GMVD Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, GMVD has a market cap of 1.8M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while GMVD trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas GMVD's P/E ratio is -0.01. In terms of profitability, BLFS's ROE is +0.13%, compared to GMVD's ROE of +2.09%. Regarding short-term risk, BLFS is less volatile compared to GMVD. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check GMVD's competition here
G Medical Innovations Holdings Ltd (NASDAQ: GMVDW)
BLFS vs GMVDW Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, GMVDW has a market cap of 1.8M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while GMVDW trades at $7.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas GMVDW's P/E ratio is N/A. In terms of profitability, BLFS's ROE is +0.13%, compared to GMVDW's ROE of +2.09%. Regarding short-term risk, BLFS is less volatile compared to GMVDW. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check GMVDW's competition here
Avinger, Inc. (NASDAQ: AVGR)
BLFS vs AVGR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, AVGR has a market cap of 1.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while AVGR trades at $0.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas AVGR's P/E ratio is -0.05. In terms of profitability, BLFS's ROE is +0.13%, compared to AVGR's ROE of +17.82%. Regarding short-term risk, BLFS is less volatile compared to AVGR. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check AVGR's competition here
NEXGEL, Inc. (NASDAQ: NXGL)
BLFS vs NXGL Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NXGL has a market cap of 1.5M. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NXGL trades at $0.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NXGL's P/E ratio is -0.25. In terms of profitability, BLFS's ROE is +0.13%, compared to NXGL's ROE of -1.33%. Regarding short-term risk, BLFS is less volatile compared to NXGL. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check NXGL's competition here
NEXGEL, Inc. (NASDAQ: NXGLW)
BLFS vs NXGLW Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, NXGLW has a market cap of 775.4K. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while NXGLW trades at $0.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas NXGLW's P/E ratio is -0.01. In terms of profitability, BLFS's ROE is +0.13%, compared to NXGLW's ROE of -1.33%. Regarding short-term risk, BLFS is less volatile compared to NXGLW. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check NXGLW's competition here
Lucyd, Inc (NASDAQ: LUCYW)
BLFS vs LUCYW Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, LUCYW has a market cap of 296.1K. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while LUCYW trades at $0.06.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas LUCYW's P/E ratio is N/A. In terms of profitability, BLFS's ROE is +0.13%, compared to LUCYW's ROE of -0.89%. Regarding short-term risk, BLFS is less volatile compared to LUCYW. This indicates lower risk in terms of short-term price fluctuations for BLFS.Check LUCYW's competition here
Antares Pharma, Inc. (NASDAQ: ATRS)
BLFS vs ATRS Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ATRS has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ATRS trades at $5.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ATRS's P/E ratio is 14.95. In terms of profitability, BLFS's ROE is +0.13%, compared to ATRS's ROE of +0.31%. Regarding short-term risk, BLFS is more volatile compared to ATRS. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ATRS's competition here
Invuity, Inc. (NASDAQ: IVTY)
BLFS vs IVTY Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, IVTY has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while IVTY trades at $7.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas IVTY's P/E ratio is -3.80. In terms of profitability, BLFS's ROE is +0.13%, compared to IVTY's ROE of -2.40%. Regarding short-term risk, BLFS is more volatile compared to IVTY. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check IVTY's competition here
Apria, Inc. (NASDAQ: APR)
BLFS vs APR Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, APR has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while APR trades at $37.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas APR's P/E ratio is 22.59. In terms of profitability, BLFS's ROE is +0.13%, compared to APR's ROE of +9.81%. Regarding short-term risk, BLFS is more volatile compared to APR. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check APR's competition here
Hill-Rom Holdings, Inc. (NYSE: HRC)
BLFS vs HRC Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, HRC has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while HRC trades at $155.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas HRC's P/E ratio is 41.92. In terms of profitability, BLFS's ROE is +0.13%, compared to HRC's ROE of +0.14%. Regarding short-term risk, BLFS is more volatile compared to HRC. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check HRC's competition here
Analogic Corporation (NASDAQ: ALOG)
BLFS vs ALOG Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, ALOG has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while ALOG trades at $83.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas ALOG's P/E ratio is 40.93. In terms of profitability, BLFS's ROE is +0.13%, compared to ALOG's ROE of -0.15%. Regarding short-term risk, BLFS is more volatile compared to ALOG. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check ALOG's competition here
IntriCon Corporation (NASDAQ: IIN)
BLFS vs IIN Comparison October 2026
BioLife Solutions, Inc. (NASDAQ: BLFS) plays a significant role within the Healthcare sector. Its performance on the NASDAQ reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BLFS stands at 1.9B. In comparison, IIN has a market cap of 0. Regarding current trading prices, BLFS is priced at $38.61 on the NASDAQ, while IIN trades at $24.23.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BLFS currently has a P/E ratio of 37.49, whereas IIN's P/E ratio is 226.45. In terms of profitability, BLFS's ROE is +0.13%, compared to IIN's ROE of -0.00%. Regarding short-term risk, BLFS is more volatile compared to IIN. This indicates higher risk in terms of short-term price fluctuations for BLFS.Check IIN's competition here